Zoetis Inc. $ZTS Shares Sold by King Luther Capital Management Corp

King Luther Capital Management Corp lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 18.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 850,931 shares of the company’s stock after selling 193,532 shares during the quarter. King Luther Capital Management Corp’s holdings in Zoetis were worth $107,064,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Malaga Cove Capital LLC purchased a new stake in Zoetis in the 4th quarter valued at $280,000. Smithfield Trust Co boosted its position in shares of Zoetis by 4.2% during the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after acquiring an additional 92 shares during the last quarter. AR Asset Management Inc. boosted its position in shares of Zoetis by 11.8% during the 4th quarter. AR Asset Management Inc. now owns 37,864 shares of the company’s stock valued at $4,764,000 after acquiring an additional 4,000 shares during the last quarter. Allstate Corp boosted its position in shares of Zoetis by 106.1% during the 4th quarter. Allstate Corp now owns 32,227 shares of the company’s stock valued at $4,055,000 after acquiring an additional 16,592 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Zoetis by 25.2% during the 4th quarter. Fisher Asset Management LLC now owns 2,975 shares of the company’s stock valued at $374,000 after acquiring an additional 599 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 in the last quarter. Insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $80.36 on Wednesday. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $172.23. The business’s fifty day simple moving average is $106.72 and its 200-day simple moving average is $117.88. The firm has a market cap of $33.69 billion, a PE ratio of 13.33, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the company earned $1.48 EPS. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ZTS. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Morgan Stanley reissued an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Finally, Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.